We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

Our strategic vision

Our goal is to become a global leader in precision medicine for the treatment of neurodegenerative diseases. To that aim, we are executing a clear business strategy around three pillars: Alzheimer’s disease, other neurodegenerative diseases and NeuroOrphan indications, and diagnostics.

(1) Progressive supranuclear palsy; (2) Neurodegenerative diseases

Our approach

Advancing our product candidates, in partnership or alone, from clinical development to regulatory approval and potential commercialization. Our products include:

 

Semorinemab

Our collaboration partner, Genentech along with Roche, is currently conducting the clinical development of semorinemab through two Phase 2 clinical studies. The first Phase 2 study (TAURIEL) conducted in prodromal to mild Alzheimer’s disease patients started in Q4 2017, and the second Phase 2 study (LAURIET) conducted in moderate Alzheimer’s disease patients started in the Q1 2019. Semorinemab is proposed to slow the prion-like propagation of Tau pathology which coincides with both clinical symptoms and disease progression in Alzheimer’s disease.

ACI-35

Janssen Pharmaceuticals and AC Immune moved the anti-Tau vaccine program forward with the initiation of a Phase 1b/2a in Q3 2019 to evaluate ACI-35.030, an anti-phospho-Tau (pTau) vaccine; ACI-35.030 targets pathological Tau and is intended as a disease-modifying treatment for AD and other Tauopathies.

MorphomerTM Tau

In collaboration with our partner, Eli Lilly and Company, we are researching and developing Tau Morphomer aggregation inhibitor small molecules with a first indication in Alzheimer’s disease. We entered ACI-3024, our lead compound, into Phase 1 in Q3 2019.

ACI-24

We own the global rights to ACI-24 and we continue to develop ACI-24 in-house as a therapeutic candidate.

ACI-24 for Alzheimer’s disease

One Phase 2 study commenced in October 2018 in order to assess the safety, tolerability, immunogenicity and target engagement of ACI-24 formulations using intramuscular injections and analyze ACI-24’s effects on brain amyloid assessed by PET imaging when given by the intramuscular route in a larger cohort size. The previous Phase 1/2 study has been completed and the clinical study report was finalized in 2019.

ACI-24 for Down syndrome

Our Phase 1b clinical study of ACI-24 for individuals with Down syndrome, intended to assess safety, tolerability and immunogenicity at two doses, is ongoing for participants in the high dose cohort. Participants from the low dose cohort have fully completed the study. To date, no serious adverse events and no early withdrawal have been observed in any study participants, thus supporting a favorable safety and tolerability profile.

Crenezumab

The parent of our collaboration partner discontinued, as of January 2019, the Phase 3 clinical trials in Alzheimer’s disease but is continuing the Colombian prevention trial in genetically pre-disposed people at risk of developing familial Alzheimer’s disease. The overall beneficial safety profile was confirmed in the CREAD studies, supporting crenezumab’s application in healthy individuals with risk of developing Alzheimer’s disease.

Diagnostic candidates

In addition to the above product candidates, we will continue to develop our complementary diagnostic product candidates for Tau (with Life Molecular Imaging), alpha-synuclein and TDP-43 to advance these through clinical development, either independently or with collaboration partners.